A former administrator for the Centers for Medicare and Medicaid Services (CMS) and former commissioner of the Food and Drug Administration (FDA), Dr. Mark B. McClellan studies health-care policy and regulation at the AEI-Brookings Joint Center. A doctor and economist by training, he is developing and implementing ideas to drive improvements in high-quality, innovative, affordable health care. While at the FDA and CMS, Dr. McClellan developed and implemented major reforms in health policy, including the Medicare prescription drug benefit, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care.

- Associate Professor of Economics and of Medicine, Stanford University, 1995-present

- Administrator, Centers for Medicare and Medicaid Services, 2004-2006

- Commissioner, Food and Drug Administration, 2002-2004

- Member, President’s Council of Economic Advisers and Senior Director for Health Care, White House, 2001-2002

- Member, Institute of Medicine, 2003-present

- Research Associate, National Bureau of Economic Research, 1995-2001, 2006-present

- National Fellow, Hoover Institution, Stanford University, 2000-2001

- Director, Program on Health Outcomes Research, Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University, 1999-2001

- Associate Editor, Journal of Health Economics, 1998-2001

- Deputy Assistant Secretary for Economic Policy, U.S. Department of the Treasury, 1998-1999

Education

Ph.D., Economics, Massachusetts Institute of Technology

M.D., Harvard University-Massachusetts Institute of Technology Division of Health Sciences and Technology

M.P.A., Harvard University

B.A., University of Texas at Austin

Articles and Short Publications

Drug Safety Reform at the FDA Medicare Part D and Prescription Drug Prices

Events

Oncology Drug Development: Rethinking FDA Oversight The 2007 State of the Union Can Government Price Negotiation Work for the Medicare Drug Benefit?

Speaking Engagements

Medicare Advantage and the Federal Budget Fundamental Improvements in Drug Safety for the 21st Century Fundamental Improvements in Drug Safety for the 21st Century